Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Summary: Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal MET ex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.

Original languageEnglish (US)
Pages (from-to)802-805
Number of pages4
JournalCancer Discovery
Volume5
Issue number8
DOIs
StatePublished - Aug 1 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker'. Together they form a unique fingerprint.

  • Cite this